The impact of socioeconomic position on stage at diagnosis and survival in colorectal cancer patients in Switzerland

Anita Feller1,2, Kurt Schmidlin1, Andrea Bordoni1, Christine Bouchardy1, Jean-Luc Buillardi4, Bertrand Camery6, Isabelle Konzelmann3, Manuela Maspoli8, Miriam Wanner9, Marcel Zwahlen1, Kerri M. Clough-Gorr1,10

1Institute of Social and Preventive Medicine (ISPM), Bern; 2National Institute for Cancer Epidemiology and Registration (NICER), Zurich; 3Ticino Cancer Registry, Locarno; 4Geneva Cancer Registry, Geneva; 5Vaud Cancer Registry, Lausanne; 6Fribourg Cancer Registry, Fribourg; 7Valais Cancer Registry, Sion; 8Neuchâtel and Jura Cancer Registry, Neuchâtel; 9Cancer Registry Zurich and Zug, Zurich; 10National Cancer Registry Ireland, Cork

1. Background

- Studies outside of Switzerland have reported socioeconomic inequalities in colorectal cancer (CRC) stage at diagnosis and survival [1-4].

2. Aim

- To investigate the impact of socioeconomic position (SEP) and further demographic characteristics
  - on colorectal cancer (CRC) stage at diagnosis
  - on CRC-specific survival

- To investigate whether potential survival inequalities can be explained by differences in stage at diagnosis and/or sociodemographic factors.

3. Methods

Data Source

- This study used population-based CRC data (ICD-10 C18-C20) from seven Swiss cantonal cancer registries 2001-2008 (N=10,088) anonymously linked to the Swiss National Cohort (SNC). Follow-up information on vital status was available until the end of 2013.

Socioeconomic position (SEP)

- SEP was defined based on education (low/middle/high).

Statistical analysis

- The association between cancer stage at presentation and SEP was investigated using logistic regressions (UICC stage I versus II-IV) reporting Odds Ratios (OR).

- Survival was analysed using competing risk regressions based on Fine and Gray’s proportional hazard model. All underlying causes of death other than CRC were classified as competing risks. Results were reported as sub-hazard ratios (SHRs) for the risk of dying due to CRC.

- For stage at presentation and survival analysis, we calculated four models including the following covariates:
  - Model 1 - SEP
  - Model 2 - Model 1 plus age at diagnosis
  - Model 3 - Model 2 plus urbanity and language region
  - Model 4 - Model 3 plus tumour localisation (and stage at diagnosis for survival analysis)

4. Results

Odds ratios (OR) of later colorectal cancer stage at diagnosis

<table>
<thead>
<tr>
<th>SEP</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>High SEP (ref.)</td>
<td>[0.81, 0.95]</td>
<td>[0.81, 0.95]</td>
<td>[0.81, 0.95]</td>
<td>[0.81, 0.95]</td>
</tr>
<tr>
<td>Low SEP</td>
<td>[0.82, 0.96]</td>
<td>[0.82, 0.96]</td>
<td>[0.82, 0.96]</td>
<td>[0.82, 0.96]</td>
</tr>
</tbody>
</table>

Sex

- OR 1.08 (0.96-1.21)

Age at diagnosis

- OR 1.07 (1.06-1.18)

Sub-hazard ratios (SHR) of risk of colorectal cancer death among CRC patients

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td>SHR</td>
<td>SHR</td>
<td>SHR</td>
</tr>
<tr>
<td>SEP</td>
<td>[0.89, 1.03]</td>
<td>[0.89, 1.03]</td>
<td>[0.89, 1.03]</td>
</tr>
<tr>
<td>Low SEP</td>
<td>[0.89, 1.03]</td>
<td>[0.89, 1.03]</td>
<td>[0.89, 1.03]</td>
</tr>
</tbody>
</table>

5. Novelty and Impact

- This is the first population-based study in Switzerland investigating socioeconomic and demographic inequalities in stage at diagnosis and survival among CRC patients.

- In Switzerland, people of low SEP are diagnosed at later stages.

- Survival differences by SEP are explained by SEP disparities at stage at presentation.

- Non-Swiss and patients living in non-urban areas showed poorer survival.

- Swiss public health strategies should facilitate equal access to CRC screening and optimal CRC care for all social groups and in all regions of Switzerland.

6. References


7. Contact

Anita Feller
Institute of Social and Preventive Medicine (ISPM)
University of Bern
Fritschinhofweg 11
3012 Bern
Switzerland
anita.feller@ispm.unibe.ch

Kerri M. Clough-Gorr
National Institute for Cancer Epidemiology and Registration
c/o University of Zurich
Hirschengraben 82
8001 Zurich
Switzerland
anita.feller@nicer.org